XBI news

State Street(R) SPDR(R) S&P(R) Biotech · Biotechnology · United States

Stories about this fund's companies, ranked by fund weight and recency. Times are local.

24/7 Wall St. · 28 Oct 2026, 16:04 UTC
Moderna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge Higher
2.1% of XBI
The Wall Street Journal · 28 Oct 2026, 20:17 UTC
Here's Why Moderna's CEO Isn't Fazed by Its Cancer-Vaccine Selloff
1.4% of XBI
TheStreet · 28 Oct 2026, 19:33 UTC
Breakthrough cancer vaccine catches Wall Street's attention
1.4% of XBI
Seeking Alpha · 28 Oct 2026, 16:22 UTC
Moderna: ESMO Answered The Science, Q3 Has To Answer The Money (NASDAQ:MRNA) | Seeking Alpha
1.4% of XBI
Where to buy XBI
- [Broker A]Visit ↗
- [Broker B]Visit ↗
[Affiliate and risk wording from the law firm]
Investing.com · 28 Oct 2026, 14:13 UTC
Why is Moderna stock rebounding today? By Investing.com
1.4% of XBI
Investing.com · 28 Oct 2026, 14:08 UTC
Why is Twist Bioscience stock surging today? By Investing.com
1.4% of XBI
Where to buy XBI
- [Broker A]Visit ↗
- [Broker B]Visit ↗
[Affiliate and risk wording from the law firm]
Seeking Alpha · 28 Oct 2026, 12:10 UTC
Fidelity Growth Company Fund Q3 2026 Commentary (FDGRX) | Seeking Alpha
1.4% of XBI
wallstreet:online · 28 Oct 2026, 12:05 UTC
Twist Bioscience Expands High-Throughput Antibody Characterization with Launch of Express Screening Antibodies
1.4% of XBI
Seeking Alpha · 28 Oct 2026, 20:02 UTC
Biogen anticipates $250M of run rate synergies by end of 2027 as it raises 2026 non-GAAP EPS to $12.20-$13 (NASDAQ:BIIB) | Seeking Alpha
1.0% of XBI
Seeking Alpha · 28 Oct 2026, 20:00 UTC
Biogen Inc. (BIIB) Q3 2026 Earnings Call Transcript | Seeking Alpha
1.0% of XBI
Seeking Alpha · 28 Oct 2026, 19:01 UTC
Biogen Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:BIIB) 2026-10-28 | Seeking Alpha
1.0% of XBI
Yahoo! Finance · 28 Oct 2026, 16:03 UTC
This Dividend Powerhouse Is Heading Into Q3 Earnings With Plenty at Stake
1.0% of XBI
The Manila times · 28 Oct 2026, 20:27 UTC
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
0.9% of XBI
Investing.com · 28 Oct 2026, 15:42 UTC
Incyte earnings up next: Analysts eye loss amid pipeline gains By Investing.com
1.0% of XBI
Investing.com · 28 Oct 2026, 13:52 UTC
Earnings call transcript: Biogen beats Q3 2026 estimates as growth portfolio expands By Investing.com
1.0% of XBI
Market Screener · 28 Oct 2026, 14:41 UTC
Adagene Inc. Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte?S Inca33890 in Patients with Microsatellite Stable Colorectal Cancer
1.0% of XBI
Quartz · 28 Oct 2026, 14:15 UTC
New weight-loss drugs: what 6 drugmakers are testing
1.0% of XBI
Investing.com · 28 Oct 2026, 13:42 UTC
Exelixis stock hits all-time high at 65.62 USD By Investing.com
1.0% of XBI
The Wall Street Journal · 28 Oct 2026, 11:09 UTC
Biogen Swings to Loss, Logs Higher Sales
1.0% of XBI
Seeking Alpha · 28 Oct 2026, 11:04 UTC
Biogen posts Q3 beat on multiple sclerosis drugs (BIIB:NASDAQ) | Seeking Alpha
1.0% of XBI

XBI news

Where to buy XBI

Where to buy XBI